Toboroz
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
NCT07672769· 2. fázis· Faron Pharmaceuticals Ltd· Forrás
Toboroz
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
NCT07871864· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Contact: Anu Huurre
Még nem toboroz
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
NCT07719348· 1/2. fázis· Servier· Forrás
Még nem toboroz
Effects of General Anaesthetic Agents on the Efficacy of Electroconvulsive Therapy and EEG Changes in Patients with Depression
2025-524829-40-00· 4. fázis· Varsinais-Suomen hyvinvointialue· Forrás
Még nem toboroz
TARGET-EBV in MS: Targeting Epstein Barr Virus with Tenofovir Alafenamide Fumarate in multiple sclerosis
2025-522140-40-00· 2. fázis· Oslo University Hospital HF· Forrás
Toboroz
Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)
2023-505575-69-01· 3. fázis· Institut Gustave Roussy· Forrás
Még nem toboroz
Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Gastric Cancer
2026-526494-42-00· 2. fázis· Varsinais-Suomen hyvinvointialue· Forrás
Toboroz
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137· 3. fázis· Eli Lilly and Company· Forrás
Még nem toboroz
Hydroxychloroquine in progressive MS
2025-522573-11-00· 2. fázis· Varsinais-Suomen hyvinvointialue· Forrás
Toboroz
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· 3. fázis· University Of Cologne· Forrás
Toboroz
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
A clinical proof-of-concept study to reduce smoldering inflammation in progressive MS
2024-517336-21-00· 2. fázis· University Of Turku· Forrás
Még nem toboroz
Fecal microbiota transplantation in patients receiving infliximab and vedolizumab for ulcerative colitis: A randomized controlled trial
2024-520373-12-00· 4. fázis· Varsinais-Suomen hyvinvointialue· Forrás
Toboroz
Clinical use of USPIO contrast media in the assessment of pelvic lymph node metastasis in rectal cancer.
2024-514831-34-00· 3. fázis· Varsinais-Suomen hyvinvointialue· Forrás
Toboroz
Transdermal estradiol and exercise in mitigating adverse effects of androgen deprivation therapy for prostate cancer radiation therapy (ESTRACISE)
2023-504704-28-00· 2. fázis· Varsinais-Suomen hyvinvointialue· Forrás
Toboroz
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
NCT05476939· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Fut, nem toboroz
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
NCT05206773· 3. fázis· Sanofi· Forrás
Toboroz
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.
2024-510578-25-00· 3. fázis· The University Of Birmingham· Forrás
Fut, nem toboroz
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
NCT04557059· 3. fázis· Janssen Pharmaceutica N.V., Belgium· Forrás
Toboroz
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· 1/2. fázis· University of Birmingham· Forrás
Toboroz
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576· 3. fázis· Mats Heyman· Forrás
Fut, nem toboroz
Effect of Cladribine Treatment on Microglial Activation in the CNS
NCT04239820· 4. fázis· Turku University Hospital· Forrás
Toboroz
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796· 2/3. fázis· Celgene· Forrás
Fut, nem toboroz
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022· 2. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma
NCT02265770· 2/3. fázis· Centre Leon Berard· Forrás
Toboroz
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
2024-516078-31-00· 2/3. fázis· The University Of Birmingham· Forrás
Fut, nem toboroz
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
NCT02066220· 2/3. fázis· Universitätsklinikum Hamburg-Eppendorf· Forrás
Toboroz
NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years
NCT01828489· 3. fázis· Vaestra Goetalandsregionen· Forrás